Let's Talk TB
Global Impact
In 2023, tuberculosis (TB) claimed the lives of approximately 1.25 million people, including 161,000 individuals living with HIV. After three years of being overshadowed by COVID-19, TB has likely regained its position as the leading cause of death from a single infectious agent worldwide.1
It remains the deadliest disease among people with HIV and continues to be a major contributor to deaths linked to antimicrobial resistance-a growing global health threat.1
400 thousand developed multidrug-resistant or rifampicin-resistant TB in 2023.2
8.2 million newly diagnosed people in 2023.2
1.25 million annual deaths in 2023.2
Text1
Supporting Accurate TB Diagnosis and Monitoring
We help you to gain comprehensive insights by first detecting Mycobacterium tuberculosis (MTB) and possible resistance to first-line treatment options and then, if needed, supporting physicians as they tailor the optimal treatment regimen with full phenotypic drug susceptibility testing. Better insights lead to more informed decision making and more appropriate treatment so that you can improve laboratory efficiencies and achieve a streamlined diagnostic pathway.
Don’t Miss This: A Fresh Look at TB Challenges & Diagnostics in Just 5 Minutes
Specimen collection
Specimen Preparation
Digestion, decontamination, plating, staining and microscopy, with BD BBL™ Mycoprep, BD BBL™ Acid Fast and Fluorescent Stains and BD BBL™ Prepared Media
MTB, RIF, INH (katG and inhA) results with one single assay of BD MAX™ MDR-TB
Manual and fully automated liquid culture with BD BACTEC™ MGIT™ Systems
Direct, fast MTBc ID from culture with BD MGIT™ TBcID Identification Test
SIRE and PZA first line antimicrobial reagents DST with BD BACTEC™ MGIT™ Systems
Data management and reporting tools with BD EpiCenter™ Data Management System TB-eXIST Extented Individual Susceptilibility Testing (None - CE Marked Product)
We are thrilled to announce our Global Webinar on TB Testing titled:“A Holistic Approach to TB Testing: Integrating BD MAX™ Multi Drug Resistant Tuberculosis (MDR-TB) assay and BD BACTEC™ Mycobacteria Growth Indicator Tube (MGIT)”.
This webinar presents an exciting opportunity to connect with our customers, offering them critical insights into the importance of accurate and timely diagnosis of tuberculosis, especially MDR-TB. With your support, we can maximize its impact by driving strong attendance and delivering real value to our customers.
- Date: Wednesday, January 14th, 2026
- Time: 10 AM PST, 1 PM EST, 7 PM CET
- Register here
